Key facts
- This page summarizes Wellington Biomedical Innovation Master Investors (Cayman) I L.P.'s Form 4 filing for Zenas BioPharma, Inc. (ZBIO).
- 6 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 18 Sep 2024, 17:16.
Wellington Biomedical Innovation Master Investors (Cayman) I L.P. - 16 Sep 2024 Form 4 Insider Report for Zenas BioPharma, Inc. (ZBIO)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- ZBIO
- Reported as of
- 16 Sep 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 18 Sep 2024, 17:16:21 UTC
- Prior SEC filing
- 12 Sep 2024
- Source filing
- View source filing
- Reporting owner signature
- Wellington Biomedical Innovation Master Investors (Cayman) I L.P. By: Wellington Management Company LLP, as Investment Adviser By: /s/ Jennifer C. Boylan, Authorized Signatory
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Wellington Biomedical Innovation Master Investors (Cayman) I L.P. filed Form 4 for Zenas BioPharma, Inc. (ZBIO) on 18 Sep 2024.
Change
- Previous filing in this sequence was filed on 12 Sep 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ZBIO
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +180,635
- Change %
- Price
- Shares after
- 180,635
- Date
- 16 Sep 2024
- Ownership
- Direct
- Footnotes
- F1
ZBIO
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +420,271
- Change %
- +233%
- Price
- Shares after
- 600,906
- Date
- 16 Sep 2024
- Ownership
- Direct
- Footnotes
- F1, F2
ZBIO
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +200,718
- Change %
- +33%
- Price
- Shares after
- 801,624
- Date
- 16 Sep 2024
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ZBIO
transaction
Derivative
Series A Convertible Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -1,568,480
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 16 Sep 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 180,635
- Exercise price
- Footnotes
- F1
ZBIO
transaction
Derivative
Series B Convertible Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -3,649,263
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 16 Sep 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 420,271
- Exercise price
- Footnotes
- F2
ZBIO
transaction
Derivative
Series C Convertible Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -1,742,858
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 16 Sep 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 200,718
- Exercise price
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Wellington Biomedical Innovation Master Investors (Cayman) I L.P. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 3 footnotes
Footnote F1
On September 16, 2024, the shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.
Footnote F2
On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.
Footnote F3
On September 16, 2024, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.